Nanobody-based CAR NK cells for possible immunotherapy of MICA tumors.

Verhaar, Elisha R [PCMM, Boston Children's Hospital - Harvard Medical School] van Keizerswaard, Willemijn J C [PCMM, Boston Children's Hospital - Harvard Medical School] Knoflook, Anouk [PCMM, Boston Children's Hospital - Harvard Medical School] Balligand, Thomas [PCMM, Boston Children's Hospital - Harvard Medical School] Ploegh, Hidde L [PCMM, Boston Children's Hospital - Harvard Medical School]

The glycoproteins MICA and MICB are upregulated on the surface of cells undergoing stress, for instance due to (viral) infection or malignant transformation. MICA/B are the ligands for the activating receptor NKG2D, found on cytotoxic immune cells like NK cells, CD8 T cells, and γδ T cells. Upon engagement of NKG2D, these cells are activated to eradicate the MICA/B-positive targets, assisted by the secretion of cytokines. Nanobodies, or VHHs, are derived from the variable regions of camelid heavy-chain only immunoglobulins. Nanobodies are characterized by their small size, ease of production, stability, and specificity of recognition. We generated nanobodies that recognize membrane-bound MICA with high affinity. Here, we use these nanobodies as building blocks for a chimeric antigen receptor (CAR) to establish VHH-based CAR NK cells. These anti-MICA nanobody-based CAR NK cells recognize and selectively kill MICA-positive tumor cells in vitro and in vivo. We track localization of the VHH-based CAR NK cells to MICA-positive lung metastases by immuno-positron emission tomography imaging.